ArticleDermatology and therapy2022

Efficacy and Safety of Certolizumab Pegol in Japanese Patients with Generalized Pustular Psoriasis and Erythrodermic Psoriasis: 52-Week Results.

Yukari Okubo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.